Exousia Pro Cancels 47M Dilutive Shares, Projects Significant Revenue from Telehealth Acquisitions
MAJI sits 31% above its 52-week low of $0.024 on light trading volume (0.2× avg).
Summary
Exousia Pro, Inc. (MAJI) announced the strategic cancellation of derivative securities convertible into 47 million shares of common stock, effectively eliminating a massive source of future dilution. This was achieved via an exchange agreement involving 2 million LMMY shares. Concurrently, the company reported significant progress towards definitive agreements for three telehealth acquisitions, with one target entity already scaling monthly revenue from $80,000 to $135,000 and projecting a transformative $240,000 per month from a new exclusive supplier partnership. This news provides a strong counter-narrative to the recent 1-A POS filing on February 19, 2026, which outlined a highly dilutive Regulation A offering; the elimination of 47 million shares addresses a separate, even larger potential dilution event. The cancellation of such a substantial amount of potential dilution is a monumental positive for MAJI, given its micro-cap status, as it removes a significant overhang and de-risks the stock. The projected revenue from the telehealth acquisitions also represents a substantial and transformative increase in the company's financial outlook. Traders should monitor the finalization of the telehealth acquisition agreements, the company's planned share buyback program to neutralize Reg A dilution, and the outcome of the March 13th mediation for further share cancellations.
At the time of this announcement, MAJI was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.02 to $0.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.